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Abstract
There is an urgent requirement to identify which clinical settings are in most need of COVID-
19 tests and the priority role(s) for tests in these settings to accelerate the development of
tests fit for purpose in health and social care across the UK. This study sought to identify
and prioritize unmet clinical needs for COVID-19 tests across different settings within the
UK health and social care sector via an online survey of health and social care professionals
and policymakers. Four hundred and forty-seven responses were received between 22nd
May and 15th June 2020. Hospitals and care homes were recognized as the settings with
the greatest unmet clinical need for COVID-19 diagnostics, despite reporting more access
to laboratory molecular testing than other settings. Hospital staff identified a need for diag-
nostic tests for symptomatic workers and patients. In contrast, care home staff expressed
an urgency for screening at the front door to protect high-risk residents and limit transmis-
sion. The length of time to test result was considered a widespread problem with current
testing across all settings. Rapid tests for staff were regarded as an area of need across
general practice and dental settings alongside tests to limit antibiotics use.
Introduction
Testing plays an integral role in the international response to the current coronavirus pandemic,
facilitating national surveillance and guiding patient management. Testing strategies have been
heavily scrutinized, and it is widely acknowledged that the tests currently available are far from
ideal. For example, reverse transcription polymerase chain reaction (RT-PCR) based tests, the
most commonly used laboratory-based tests for determining current infection, has a false nega-
tive rate of around 20% (depending on symptom duration, sampling technique, and site) [1].
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The industry response has been unprecedented; by the 17th of July 2020, 746 tests had been
developed or are under development [2]. Although this extraordinarily fast development offers
hope that the current testing shortfalls can be overcome, this creates a real challenge for diag-
nostic regulatory bodies. For many years, the conversion of diagnostic innovation from bench
to clinical practice has been riddled with problems and is notoriously slow [3]. A rapid evalua-
tion pipeline is required to ensure that tests offering real health benefits are integrated into
practice within a timeframe that will support international efforts to curtail the transmission of
SARS-CoV-2.
In March 2020, the World Health Organization (WHO) outlined a research roadmap rec-
ommending the development of Target Product Profiles (TPPs) to drive the research and
innovation process around new diagnostic tests for COVID-19 [4]. A TPP is a document that
summarises in advance the desirable and minimally acceptable specifications for a new test to
address a well-defined clinical need. The overarching aim is to ensure that innovation efforts
are focused on developing ‘fit for purpose’ tests [5,6]. The National Institute for Health and
Care Excellence (NICE) have recently begun an economic modeling exercise to help inform
TPP specifications for COVID-19 tests [7].
At the core of TPP development is the scoping and definition of unmet clinical needs [5].
Tests often have numerous roles in clinical practice across multiple clinical settings (e.g., pri-
mary and secondary care) and positions in a care pathway (e.g., to diagnose or to monitor dis-
ease) [8]. There is an urgent need to identify which health and social care settings are most in
need of COVID-19 tests, and the priority role(s) for tests in these settings, particularly ahead
of the winter season, where other respiratory viral-like illnesses will also be in circulation.
To this end, the National Institute for Health Research (NIHR) MedTech and In Vitro
Diagnostics (IVD) Co-operatives (MICs), on behalf of the COVID-19 National DiagnOstic
Research and Evaluation Platform (CONDOR) [9], designed an online survey at pace to gather
opinion from health and social care professionals and policymakers on unmet clinical needs
for COVID-19 tests in the UK. The primary objective of the survey was to determine which
settings are in most need of a new COVID-19 test and determine the priority role(s) for new
tests within each setting. The results will be used to help prioritise and refine TPP develop-
ment, plan for winter allocation of tests, and inform economic modeling carried out by the
NICE diagnostics assessment programme. Interim reports were shared with the Department
of Health and Social Care (DHSC) and NICE on 29/05/2020 and 28/06/2020 to inform deci-
sions around UK national testing policies.
Materials and methods
This project was approved as a service evaluation (ID:10151) by the Newcastle Upon Tyne
NHS Hospitals Foundation Trust. Consent to participate was obtained if the respondent read
the information on the first page of the survey and clicked ‘Consent to participate’ (see S1
File). The development and reporting of the survey followed good practice guidelines pub-
lished by Kelley et al. [10] and highlighted by the Enhancing the QUAlity and Transparency
Of health Research (EQUATOR) network [11]. The survey questions were written based on an
initial list of priority use cases developed by the DHSC COVID-19 Test Approvals Groups.
Survey design, development, and dissemination
Targeted respondents of this survey were health and social care professionals working in the
UK across a variety of settings, and policymakers.
The survey was voluntary and anonymized, with no personal, sensitive, or patient data col-
lected. All respondents were asked to select which setting was most in need of a novel COVID-
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19 test, and then health and social care professionals were asked to rate the importance of dif-
ferent use cases specific to the setting where they worked. The use cases described potential
uses and roles of tests at specific points in the pathway; they were technology agnostic but
described roles that could be fulfilled by molecular or serology tests. All respondents, apart
from policymakers, were asked if diagnostic testing for COVID-19 was available in the setting
in which they worked and, if so, they were asked which type of tests (e.g., molecular, serologi-
cal) were available and whether they perceived any problems with the tests.
A first draft of the questionnaire was developed using Online surveys (formerly BOS)
[12], with the support of two clinicians, and then the questionnaire was tested and revised
by the wider authorship team to improve clarity and flow. The survey was then piloted by
six hospital clinicians (one of whom worked closely with the ambulance service and
another with care homes) and one dentist before its launch, with feedback incorporated
into the survey’s final version. Piloting the survey identified problems with wording and
confirmed whether the survey functioned as intended in terms of access, navigation and
submission [13,14]. Pilot data were not included in the final analysis to avoid contamina-
tion of results [14].
The survey was launched and disseminated via a variety of networks, including the NIHR
Clinical Research Network (CRN) Coordinating Centre networks, clinical contacts of the
NIHR MICs, as well as social media (limited to Twitter and LinkedIn, to our knowledge). A
copy of the survey is available in the S1 File.
Survey analysis
A setting was required to have at least 30 respondents in order to be included in the analysis,
except for policymakers, where a smaller sample size was anticipated due to policymakers
comprising a smaller proportion of the workforce compared to health and social care
professionals.
Data processing and analysis were primarily conducted in the statistical programming lan-
guage R [15], with qualitative free-text responses analyzed in Microsoft Excel. Where appropri-
ate, combined heat maps and dendrograms were used to visualize results and identify
similarities/differences between settings using the R function ‘heatmap.2’ from the ‘gplots’
package [16]. Hierarchical clustering was performed using the complete agglomeration
method, and the Euclidean method was used to calculate the distances between the data.
Respondents selected whether they felt each use case in their specific setting was ‘More
Important’, ‘Important’ or ‘Less Important’ relative to the others in the list. A scoring system
was applied (More Important = 1, Important = 0, Less Important = -1), with the mean score
and standard deviation calculated to summarize responses. The use cases were then ranked
from the highest mean score to the lowest.
A framework for categorizing use cases was developed to facilitate the interpretation of
results. Use cases were grouped in the survey based on their intended use: ‘Screening’ (to sup-
port isolation, personal protective equipment (PPE) use and cohorting decisions), ‘Diagnostic’
(to inform both infection control and treatment stratification), ‘Prognostic’ (escalation of care
decisions) and ‘Monitoring’ (de-escalation of care and safe return to work) [17]. These were
subsequently validated and independently re-grouped. In case of disagreement, a single arbiter
resolved discrepancies. In the survey, the respondents could also suggest additional use cases
via a free text field, if they perceived them to be missing from the provided list. Based on the
previously defined framework, additional use cases were analyzed to identify responses similar
to the provided list, then independently assigned to the ‘Screening,’ ‘Diagnostic,’ ‘Prognostic,’
and ‘Monitoring’ categories.
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Patient and public involvement
Seven members of the CONDOR [9] patient and public representative panel were invited to
participate in a focus group discussion. The background, methods, and results of the survey
were presented to the group, who were then invited to comment on these aspects. The partici-
pants provided verbal and written feedback during and after the meeting which has been
incorporated into the discussion and will form the basis of a lay summary for the public to be
published on the CONDOR website [9]. They agreed that the survey addressed important
questions in relation to COVID-19 diagnostics. They raised the issues of geographical and eth-
nic representativeness of sampling, the potential omission of settings, and the importance of
including patient experiences in future surveys. This included the impact of testing on their
physical and mental health and the overall confidence of the public in COVID-19 testing.
Results
The survey was launched at 4 pm on the 22nd of May 2020 and was open until 9 am on the 15th
June 2020, receiving 447 completed responses (Table 1). It was not possible to estimate the
number of potential respondents reached due to the variety of dissemination routes used. The
distribution of survey responses over time, grouped by the setting in which the respondents
worked, is presented in S1 Fig.
Demographics of respondents
The majority of the respondents were from the North East of England (n = 217, 48.6%), with
411 respondents in total from England (92%) (Table 1).
The most common setting in which respondents worked was hospitals (n = 189, 42%), fol-
lowed by primary dental care (n = 65, 15%) and general practice (n = 55, 12%) (Table 1). The
hospice (n = 14, 3%), ambulance service (n = 9, 2%) and hospital-at-home settings (n = 3, 1%)
received less than 30 respondents.
Unmet clinical need
Settings which were deemed the highest priority were hospitals (Fig 1, 266 selections across all
settings, 55.8% of respondents) and care homes (196 selections across all settings, 41.1% of
respondents). This finding was apparent even when considering those who didn’t select their
own setting (the red bars in Fig 1). All other settings received less than 100 selections each.
Twelve policymakers completed the survey. Most of them prioritized care homes (n = 4), fol-
lowed by domestic residences (n = 3) and GP practices (n = 2), with hospitals, hospices, and
the ambulance service selected by one respondent each. Care homes were generally prioritized
by respondents working in other settings.
Use case ranking was explored in care homes with and without nursing independently, and
the results were similar, as were those for primary and secondary dental care. We then pooled
results from each of these two settings in order to increase the sample size for this and subse-
quent analyses.
The top three clinical needs for hospitals (Table 2) were all related to diagnosis to support
infection control decisions for patients presenting to the hospital (1st), for workers (2nd), and
for in-patients (3rd). For care homes, screening tests to support infection control decisions
were the most important, with a test for those at admission and workers ranked first and sec-
ond, respectively, and a test for patients potentially exposed ranked third. Respondents from
GP and dental settings showed a similar focus on infection control measures for workers, iden-
tifying the two most important needs as testing to support screening and diagnosis of workers.
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The third most important identified need was around monitoring for both settings. The dental
setting showed a preference for a test to support safe return to work and the GP setting a test
discharge patients into care homes safely. Respondents from the prison setting preferred a test
to identify prisoners with COVID-19 at admission with symptoms (1st), and those with infec-
tion who are asymptomatic (2nd). The third most important identified need was to support
workers in their self-isolation decisions when symptomatic; however, this had a much lower
score than the first two ranked needs. No respondents across settings seemed to consider the
few prognostic use cases proposed as being particularly important.
Some respondents suggested additional needs for clinical tests for COVID-19. While 32
(66.6%) of these could be mapped to existing use cases (the majority of which were for screen-
ing tests, n = 6 for patients, n = 14 for staff and n = 4 for community screening), 16 (33.3%)
Table 1. Characteristics of survey respondents.
Respondents, n 447
Respondents’ location, n (%)
North East 217 (48.6) North West 55 (12.3)
South East 33 (7.4) South West 21 (4.7)
East Midlands 21 (4.7) Greater London 20 (4.5)
West Midlands 19 (4.3) Scotland 19 (4.3)
Yorkshire and Humber 16 (3.6) Wales 12 (2.7)
East of England 9 (2.0) Northern Ireland 5 (1.1)
Respondents’ clinical setting, n (%)
Hospital� 189 (42.3) Primary dental care 65 (14.5)
General practice 55 (12.3) Prison 30 (6.7)
Secondary dental care1 26 (5.8) Care home without nursing 22 (4.9)
Care home with nursing 22 (4.9) Hospice 14 (3.1)
Health policy 12 (2.7) Ambulance 9 (2.0)
Hospital-at-home 3 (0.7)
�Hospital sections where respondents in that setting worked, n (%)2
Outpatient clinic 48 (20.3) General medicine ward 28 (11.9)
Other 24 (10.2) Ophthalmology 22 (9.3)
Emergency Department 19 (8.1) Intensive Care Unit 19 (8.1)
Oncology 12 (5.1) Gastroenterology/Colorectal 10 (4.2)
General surgery ward 9 (3.8) Respiratory 8 (3.4)
Laboratory 7 (3.0) Theatres 6 (2.5)
Infectious diseases 5 (2.1) Haematology 5 (2.1)
Rheumatology 4 (1.7) Neurology 4 (1.7)
Renal 3 (1.3) Endocrinology 2 (0.9)
Transplantation 1 (0.4)
Respondents’ professional experience, n (%)
10 or more years 311 (71.5) Between 5 and 9 years 71 (16.3)
Between 1 and 4 years 44 (10.1) Less than 1 year 9 (2.1)
Patient groups that respondents worked with, n (%)2
Adults 344 (45.5) Older people 232 (30.7)
Paediatrics 143 (18.9) Neonates 20 (2.6)
None 17 (2.2)
1Secondary and community dental care;
2Multiple selection enabled question.
https://doi.org/10.1371/journal.pone.0242125.t001
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were judged as new use cases by the authors (S1 and S2 Tables). Those that could not be
mapped to existing use cases, highlighted the following additional needs: tests for ‘track and
trace’, to detect immunity, to distinguish infective cases from non-active infections, to allow
safe delivery of elective surgeries, and multiplex tests (i.e., panel tests that can detect multiple
respiratory pathogens at the same time) for the winter season. Antibody tests (i.e., serology
testing) were mentioned 12 times, with the majority of respondents suggesting that antibody
tests would be useful to understand who had COVID-19, while some also recognized the
uncertainty around antibody testing.
Problems with medical tests and their availability
The settings where the respondents most frequently stated that COVID-19 tests were available
(Fig 2) were hospitals (87%), prisons (85%), and care homes (78%). The settings where the
respondents most frequently stated that no COVID-19 tests were available were dental care
(86%) and GP (74%). In all settings where COVID-19 testing was reported as being available,
molecular laboratory testing was the most common option. Serology point of care tests were
only available in GP and hospital settings.
Respondents who stated that there were no COVID-19 tests available most frequently
reported (Fig 3) that ‘Potential spread of infection’was the consequence of the lack of COVID-
Fig 1. Settings with the greatest perceived unmet clinical need for COVID-19 tests, showing votes from
respondents for their own setting (blue shading) and other settings (red shading).
https://doi.org/10.1371/journal.pone.0242125.g001
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Table 2. Unmet clinical need priorities in each setting from respondents who worked in those settings, ranked by mean score from highest (most important clinical
need) to lowest (least important clinical need).
Use cases Hospital
(n = 189)
Care homes
(n = 44)
General
Practice
(n = 55)
Dental setting
(n = 91)
Prison (n = 30)
Mean
score
Rank Mean
score
Rank Mean
score
Rank Mean
score
Rank Mean
score
Rank
SCREENING: to support isolation, PPE use and cohorting decisions
A test for those on admission to prevent transmission to existing individuals x x 0.93 1 x x x x 0.80 2
To determine whether an asymptomatic patient� has previously been
infected with COVID-19
0.07 13 0.61 9 0.20 8 0.11 9 0.27 9
A test for asymptomatic patients who have been potentially exposed 0.42 6 0.70 3 0.22 7 - x 0.53 5
A test for asymptomatic patients to support safe attendance at routine
appointments
x x x x x x 0.41 5 x x
A test for asymptomatic patients to support safe attendance at urgent
appointments to guide appropriate use of PPE and aerosol generating
procedures
x x x x x x 0.48 4 x x
A test for potentially exposed, asymptomatic workers to support self-
isolation decisions
0.43 5 0.77 2 0.67 1 0.81 1 0.60 4
To identify who among patients presenting to clinical setting for reasons
unrelated to COVID-19 can receive emergency treatment for non-COVID-
19 conditions
0.28 7 x x x x x x x x
To identify among patients presenting to clinical setting for reasons
unrelated to COVID-19 who can receive routine treatment for non-
COVID-19 conditions
0.12 11 x x 0.02 10 - x x x
DIAGNOSTIC
To determine whether a patient with flu-like symptoms has previously been
infected with COVID-19 for infection control, patient triaging and
management
0.24 10 0.66 7 0.36 4 0.16 x 0.40 7
A test for symptomatic patients presenting at the clinical setting to support
infection control
0.57 1 0.70 4 0.35 5 x x 0.83 1
A test for symptomatic patients to support safe attendance at urgent
appointments to guide appropriate use of PPE and aerosol generating
procedures
x x x x x x 0.33 6 x x
A guide for symptomatic patients to support safe attendance at routine
appointments to guide appropriate use of PPE and aerosol generating
procedures
x x x x x x 0.12 8 x x
A test for symptomatic care workers to support self-isolation decisions for
infection control
0.56 2 0.70 5 0.64 2 0.68 2 0.70 3
A test for in-patients who develop new clinical features of COVID-19
during their stay to support infection control
0.50 3 x x x x x x x
To confirm that a patient is currently infected with COVID-19 following
initial/triage testing to inform treatment choices (e.g. antibiotics/antivirals)
0.26 8 0.70 6 0.27 6 x x 0.50 6
PROGNOSTIC: escalation of care decisions
To identify who among patients with confirmed COVID-19 diagnosis could
benefit from escalation of care
0.08 12 0.61 8 0.04 9 x x 0.30 8
To identify among symptomatic individuals who could benefit from
hospital admission
x x 0.57 10 x x x x - x
To determine whether a patient with flu-like symptoms has previously been
infected with COVID-19 to support escalation of care advice
x x x x x x x 7 - x
MONITORING
A test for care workers with a confirmed COVID-19 diagnosis to inform
safe return to work
0.47 4 x x x x 0.63 3 x x
(Continued)
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19 testing in the dental setting. ‘Delays in administrating treatments to patient’ was the most fre-
quently reported response. The hierarchical cluster analysis suggested that the perceived conse-
quences of the lack of COVID-19 testing within the dental and GP settings were similar, where
the misuse of antibiotics/antibiotic resistance was frequently reported. Within the prison set-
ting, there were lower numbers reporting hospital and treatment-associated consequences.
Table 2. (Continued)
Use cases Hospital
(n = 189)
Care homes
(n = 44)
General
Practice
(n = 55)
Dental setting
(n = 91)
Prison (n = 30)
Mean
score
Rank Mean
score
Rank Mean
score
Rank Mean
score
Rank Mean
score
Rank
A test for in-patients with confirmed COVID-19 diagnosis to inform de-
escalation of care/safe discharge (into care homes) and/or to move from side
rooms
0.24 9 0.41 11 0.40 3 x x 0.10 10
Table key: ‘PPE’ = ‘personal protective equipment’, x indicates use cases that were not proposed for that setting. The three most important use cases identified by the
respondents in each setting are indicated in bold text and shaded cells.
� Term ‘patient’ refers to residents and prisoners for care homes and prisons, respectively.
https://doi.org/10.1371/journal.pone.0242125.t002
Fig 2. The availability of COVID-19 tests in each setting as reported by respondents. Primary and secondary dental settings were merged, in addition to
care homes with and without nursing. The ‘Hospital-at-home’ (n = 3), hospices (n = 14) and ambulance setting (n = 9) were excluded due to the small number
of overall respondents. Respondents were able to select multiple answers to this question. Plot key: ‘GP’ = ‘General Practice’; ‘POC’ = ‘Point of care’; ‘lab’ =
‘Laboratory.
https://doi.org/10.1371/journal.pone.0242125.g002
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Across the majority of settings, most respondents stated that there were problems with test-
ing in the setting where they worked (Fig 4). ‘Long turnaround time’ for results of COVID-19
tests was reported most frequently as the most important problem across all settings, whereas
‘Test usability’ and ‘Too expensive’ were the least reported problem (Fig 5). There were similari-
ties in the most important reported problems between hospital and GP respondents, with the
second most frequent problem in the hospital and GP setting being the ‘Poor ability to confirm
if a patient does not have COVID-19’ (sensitivity), closely followed by the ‘Poor ability to con-
firm if a patient has COVID-19 (specificity). Prison respondents reported a ‘Lack of established
protocols to inform decision making after positive/negative results’ as their most important prob-
lem. Responses from care homes and dental settings were also similar, with issues around the
availability of equipment. ‘Difficulty in obtaining a sample’ was reported more frequently for
care homes than in other settings.
The most frequent consequence associated with these problems (Fig 6) was consistently
reported as the ‘Potential spread of infection’ along with ‘Patient anxiety/discomfort,’ especially
within the GP setting and care homes, and ‘Inappropriate use of PPE’ in the dental setting.
‘Repeat testing requirement’ in prisons and GP settings was also reported as a frequent conse-
quence of these problems.
Fig 3. Perceived consequences of no COVID-19 tests being available in each setting. Primary and secondary dental settings were merged, in
addition to care homes with and without nursing. The ‘Hospital-at-home’ (n = 3), hospice (n = 14) and ambulance setting (n = 9) were excluded due to
the small number of overall respondents. A hierarchical cluster analysis indicates how similar/dissimilar the perceived consequences of no COVID-19
tests are between settings. The numbers of responses from individual settings for this particular question are displayed on the x axis (n = x). The
histogram in the top left of the plot area shows the distribution of values, and provides a key to indicate the specific color shade of different values.
https://doi.org/10.1371/journal.pone.0242125.g003
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Discussion
To our knowledge, this is the first survey of health and social care professionals and policy-
makers to identify and prioritize unmet clinical needs for medical tests for COVID-19. We
focused the survey within the UK health and social care system and covered a range of settings.
Results of this survey informed the recent guidelines in the UK around testing for COVID-19
in various settings and are informing NICE early economic modeling. These results are impor-
tant for planning policies for the next winter season when multiple respiratory conditions will
be present and diagnostic tests will be crucial for the correct identification of COVID-19
patients.
The unmet clinical need for testing
Hospital and care home settings (with and without nursing) were prioritized as being most in
need of novel COVID-19 tests. Hospitals and care homes with nursing were reported as having
greater access to testing compared to other settings, although care homes without nursing had
minimal access to testing, highlighting a clear unmet clinical need.
The data suggested that hospitals were in most need of diagnostic tests (i.e., for symptom-
atic individuals), whereas respondents from care homes require tests to screen asymptomatic
individuals. These differing roles were important for both patients and care workers across
Fig 4. Perception of problems associated with COVID-19 testing practices in each setting. Primary and secondary dental settings were merged, in addition
to care homes with and without nursing. The ‘Hospital-at-home’, hospice and ambulance setting were excluded due to the small number of overall respondents
(n<15). Respondents selected a single ’Yes’, ’No’ or ’Don’t know’ answer. The number of responses from individual settings for this particular question is
displayed on the y axis (n = x).
https://doi.org/10.1371/journal.pone.0242125.g004
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these settings. The current testing policy in UK hospitals implemented on the 5th of June 2020,
of testing every individual with potential COVID-19 symptoms [18], addresses this clinical
need (the last hospital response to the survey was on the 3rd June 2020). The more extensive
need for tests in care homes appears to reflect the increased risk for older people [19], where
early identification of COVID-19 is extremely important for appropriate use of isolation (to
decrease the risk of infection transmission) and treatment (to decrease the risk of hospital
admission or death), the two major concerns associated with the lack of testing. Although it is
important for care home residents to safely receive visitors, the overall risk to wider care home
residents needs to be minimal, highlighting the importance of early identification of new cases
and appropriate isolation use. The UK policy for care homes changed recently (27th July 2020
[20]), requiring weekly testing of staff and monthly testing of residents. This is in line with the
clinical need identified through this survey but might pose a challenge in terms of test provi-
sion. In this context, the pooling of resident samples for testing might be a reasonable solution
for screening in low prevalence conditions [21]. When a positive pool is detected, individual
testing of residents and staff might follow.
Care homes reported issues with patient discomfort and difficulty in obtaining samples (more
than others). Therefore, there is a need to develop tests that use sample types that are more readily
obtained. Multiplex tests could also be useful in this population in the winter season, where the
detection of multiple viruses is made possible through the collection of a single sample.
Fig 5. Most important perceived problems associated with COVID-19 testing in each setting. Primary and secondary dental settings were merged, in
addition to care homes with and without nursing. The ‘Hospital-at-home’, hospice and ambulance setting (n<15) were excluded due to the small number of
overall respondents. A hierarchical cluster analysis indicates how similar/dissimilar the perceived problems associated with COVID-19 testing are between
settings. The numbers of responses from individual settings for this particular question are displayed on the x axis (n = x). The histogram in the top left of the
plot area shows the distribution of values, and provides a key to indicate the specific color shade of different values.
https://doi.org/10.1371/journal.pone.0242125.g005
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The respondents from the prison setting indicated good availability of tests, with similar
needs to the hospital setting for diagnosing and screening people at the front door to limit
transmission of the virus to other prisoners. They did not have access to serology tests, but
they seemed satisfied with the tests they had available, except for the long time to results and
the lack of clear protocols to guide interpretation and actions following the results. Guidelines
and care pathways should be developed in collaboration with health and social care profession-
als working in prisons to provide effective support during the winter season. This could help
address health inequalities, which have been highlighted by the COVID-19 pandemic [22].
Interestingly, general practice and dental settings had similar needs which were mainly
focused on identifying workers with COVID-19 (symptomatic or asymptomatic) who could
transmit the disease to individuals in the community. Comparatively, these settings had lim-
ited access to COVID-19 tests and the main highlighted consequence of this was the inappro-
priate use of antibiotics. The most common new use cases stipulated by the respondents
included tests that could support the Track and Trace program, surveillance of the general
population as well as re-infection rates. Since policy decisions to limit or enhance lockdown
measures are mainly based on these numbers [23], there is a need to increase testing capacity
in these settings.
Fig 6. Perceived consequences related to the problems associated with COVID-19 testing in each setting. Primary and secondary dental settings
were merged, in addition to care homes with and without nursing. The ‘Hospital-at-home’, hospice and ambulance setting (n<15) were excluded due
to the small number of overall respondents. A hierarchical cluster analysis indicates how similar/dissimilar the perceived consequences related to the
problems associated with COVID-19 testing are between settings. The numbers of responses from individual settings for this particular question are
displayed on the x axis (n = x). The histogram in the top left of the plot area shows the distribution of values, and provides a key to indicate the specific
color shade of different values.
https://doi.org/10.1371/journal.pone.0242125.g006
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Across all settings, two main themes emerged. The first was the concern for the potential
consequences of infection transmission, followed by the concerns around the long turnaround
time for test results [24] to inform isolation decisions and PPE use. The role of treatment strat-
ification for diagnostic tests might become more important in the future, once the clinical eval-
uation of treatments for COVID-19 are concluded (e.g. REMAP-CAP [25]).
Limitations
There were limitations in the design of the survey. The survey was developed at pace, and as a
result, could have benefitted from more comprehensive piloting, encompassing respondents
from all targeted settings. The results had to be swiftly reported to inform government testing
decisions, and therefore the survey was only open for a short period of time, which resulted in
small sample sizes for some settings. Results for hospitals, care homes, general practices, and
dental settings are likely to be more robust compared to other settings.
Rapid development and dissemination of the survey were required to capture the current
picture of a fast-moving landscape. It may not have been optimal methodologically; however,
it ensured an increased impact by informing decision makers. Furthermore, the number of
misinterpreted use cases was low, ranging from 5 and 11% of the total number of respondents
in each setting, and also the percentage of new use cases that were not included was low (0–
11%). This seems to indicate good identification and clear wording of the use cases. The higher
percentage of missed and unclear use cases reported by GP respondents (11%) may reflect the
lack of piloting in that setting.
The survey was intended for response by health and social care professionals, although no
questions were incorporated to validate inclusion criteria explicitly. Questions to identify
high-risk staff were omitted.
Settings were targeted for dissemination at different times while the survey was open (see
S1 Fig for the distribution of responses over time). The responses received may reflect chang-
ing clinical needs due to the fluctuating prevalence of COVID-19 and the different availability
of tests during the pandemic. However, because the survey was only open for a short period of
time covering three weeks at the tail end of the first wave of the pandemic in the UK, these
effects are likely to be small.
The majority of the respondents worked in hospitals and in the North East of England, so
results are less representative of other settings and other regions of the UK.
Finally, a limitation of qualitative research is that people who have a strong opinion on the
subject are often the ones most likely to participate, potentially introducing selection bias.
These limitations should be taken into account when inferring any conclusions from the data
presented.
Conclusions and next steps
In this first assessment of the clinical need for COVID-19 tests among experts in the UK, a
long turnaround of results was the most commonly reported problem across all settings in
May/June 2020, the consequence of which was identified as the potential transmission of infec-
tion. This would suggest a need for more rapid testing across all settings. Since it is unlikely
that rapid near-patient testing will be available for the coming winter season to screen every-
one, more work is needed to refine the higher priority groups and to understand the role of
multiplex tests in the coming winter season.
From the current work, the groups with highest need for COVID-19 testing were identified
as (in order):
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• staff and patients with symptoms of COVID-19 in hospitals
• screening of staff, visitors and new residents in care homes
• staff in general practice and dental settings
• screening of new prisoners, visitors, existing prisoners and workers with symptoms of
COVID-19.
These needs are most likely to be met by molecular tests, which are most accurate soon
after the patient becomes infective [26]. Antibody tests seem less useful until the biology of the
disease and its relationship with immunoglobulin A (IgA), G (IgG), and M (IgM) antibodies is
clearer [27]. In care homes, quick and cheap tests with lower accuracy but frequent testing
might be appropriate for screening, as suggested by modeling [28]. Alternatively, when preva-
lence is low, pooling of samples from residents could be a sensible approach for screening resi-
dents [21]. Rapid tests (under 10 minutes) that help distinguish viral from bacterial infections
might be also useful in GP and dental setting to limit antibiotic resistance in the community.
Despite this, more work is needed to fully characterize the unmet clinical need and optimize
sample collection. It seems likely that multiplex tests will be useful in the winter season when
other respiratory viruses circulate, particularly in care homes and in older populations of
patients.
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